Search Results
405 results found for "Domain Therapeutics"
Programs (1)
- Applying Pharmacology to Drug Discovery
What makes each drug type unique to therapeutic pharmacology? 3.
Posts (290)
- Domain Therapeutics Raises $42m Series A Financing
development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration agreement with Domain Therapeutics S.A. (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic
Other Pages (112)
- Ep 81 with Dr. Christel Menet
I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
This gap is due to their unique autoproteolytic cleavage in the GAIN domain, creating a heterodimer of technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic Therapeutics North America Inc, Montréal, Québec, Canada (2) Department of Pharmacology-Physiology, Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.
- Targeting adenosine signaling for immuno-oncology
Oncology, a clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics, a biopharmaceutical company focused on GPCR in immuno-oncology." GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec
Events (2)
- Development of GPCR Ligands as Therapeutic DrugsTickets: $0.00March 20, 2025 | 2:00 PM
- Practical Quantification of Allosteric ModulationTickets: $0.00May 1, 2025 | 2:00 PM